




Ifw

TRANSMITTAL FORM (to be used for all correspondence after initial filing)		Application Number	10/730,555
		Filing Date	December 8, 2003
		First Named Inventor	Darwin et al.
		Group Art Unit	1646
		Examiner Name	Unknown
Total Number of Pages in This Submission	8 and cited references	Attorney Docket Number	19603/4292 (CRF D-3099-03)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Notice to File Missing Parts/ Incomplete Application <input type="checkbox"/> A copy of the Notice to File Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input type="checkbox"/> Request for Corrected Filing Receipt with Enclosures <input checked="" type="checkbox"/> A self-addressed, prepaid postcard for acknowledging receipt <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): PTO-1449 (6 pages) (in duplicate) 60 cited references
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 14-1138 for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Noreen L. Connolly, Esq. Nixon Peabody LLP Clinton Square, P.O. Box 31051 Rochester, New York 14603-1051 Telephone: (585) 263-1597 Fax: (585) 263-1600
Signature	Registration No. 48,987
Date	

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input checked="" type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) _____	
October 19, 2004 Date	 Signature Jo Ann Whalen Typed or printed name



PATENT
Docket No.: 19603/4292 (CRF D-3099-03)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants :	Darwin et al.)	Examiner:
)	To Be Assigned
Serial No. :	10/730,555)	
)	Art Unit:
Cnfrm. No. :	3247)	1646
)	
Filed :	December 8, 2003)	
)	
For :	MYCOBACTERIUM TUBERCULOSIS (MTB) TARGETS)	
	FOR ANTIBIOTIC THERAPY)	

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97-1.98

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office, the references listed on the attached PTO-1449 form.

Pursuant to 37 CFR § 1.97(b)(3), no fee is required. Should it be determined that a fee is required, the Commissioner is authorized to charge any additional fee to Deposit Account No. 14-1138.

Respectfully submitted,


Date: Oct. 19, 2004

Noreen L. Connolly
Noreen L. Connolly
Registration No. 48,987

NIXON PEABODY LLP
Clinton Square, P.O. Box 31051
Rochester, New York 14603-1051
Telephone: (585) 263-1597
Facsimile: (585) 263-1600

R802210.1

Certificate of Mailing - 37 CFR 1.8(a)	
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450, on the date below.	
Date <u>October 19, 2004</u>	<u>Jo Ann Whalen</u> Jo Ann Whalen



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/730,555
				Filing Date	December 8, 2003
				First Named Inventor	Darwin et al.
				Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	1	of	6	Attorney Docket Number	19603/4292 (CRF D-3099-03)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Akaike, "Role of Free Radicals in Viral Pathogenesis and Mutation," <i>Rev. Med. Virol.</i> 11(2):87-101 (2001)	
	2	Bloom et al., "Tuberculosis: Commentary on a Re-Emergent Killer," <i>Science</i> 257:1055-1064 (1992)	
	3	Benaroudj et al., "PAN, the Proteasome-Activating Nucleotidase from Archaeobacteria, is a Protein-Unfolding Molecular Chaperone," <i>Nat. Cell. Biol.</i> 2(11):833-839 (2000)	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/730,555
				Filing Date	December 8, 2003
				First Named Inventor	Darwin et al.
				Group Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	2	of	6	Attorney Docket Number	19603/4292 (CRF D-3099-03)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	4	Bryk et al., "Metabolic Enzymes of Mycobacteria Linked to Antioxidant Defense by a Thioredoxin-Like Protein," <i>Science</i> 295(5557):1073-1077 (2002)		
	5	Buchmeier et al., "A Parallel Intraphagosomal Survival Strategy Shared by <i>Mycobacterium tuberculosis</i> and <i>Salmonella enterica</i> ," <i>Molec. Microbiol.</i> 35(6):1375-1382 (2000)		
	6	Chan et al., "Killing of Virulent <i>Mycobacterium tuberculosis</i> by Reactive Nitrogen Intermediates Produced by Activated Murine Macrophages," <i>J. Exp. Med.</i> 175:1111-1122 (1992)		
	7	Chan et al., "Effects of Nitric Oxide Synthase Inhibitors on Murine Infection with <i>Mycobacterium tuberculosis</i> ," <i>Infect. Immun.</i> 63(2):736-740 (1995)		
	8	Choi et al., "Demonstration that <i>fbiC</i> is required by <i>Mycobacterium bovis</i> BCG for Coenzyme F ₄₂₀ and FO Biosynthesis," <i>J. Bacteriol.</i> 184(9):2420-2428 (2002)		
	9	Cole et al., "Deciphering the Biology of <i>Mycobacterium tuberculosis</i> from the Complete Genome Sequence," <i>Nature</i> 393:537-544 (1998); <i>erratum Nature</i> 396(190-198 (1998)		
	10	Cole et al., "Massive Gene Decay in the Leprosy Bacillus," <i>Nature</i> 409:1007-1011 (2001)		
	11	Daley et al., "An Outbreak of Tuberculosis with Accelerated Progression Among Persons Infected with the Human Immunodeficiency Virus. An Analysis Using Restriction-Fragment-Length Polymorphisms," <i>N. Engl. J. Med.</i> 326(4):231-235 (1992)		
	12	Davies K.J., "Degradation of Oxidized Proteins by the 20S Proteasome," <i>Biochimie</i> 83:301-310 (2001)		
	13	De Mot et al., "Proteasomes and Other Self-Compartmentalizing Proteases in Prokaryotes," <i>Trends Microbiol.</i> 7(2):88-92 (1999)		
	14	Dye et al., "Consensus Statement. Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country. WHO Global Surveillance and Monitoring Project," <i>JAMA</i> 282(7):677-686 (1999)		
	15	Ehrt et al., "Reprogramming of the Macrophage Transcriptome in Response to Interferon- γ and <i>Mycobacterium tuberculosis</i> : Signaling roles of Nitric Oxide Synthase-2 and Phagocyte Oxidase," <i>J. Exp. Med.</i> 194(8):1123-1140 (2001)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/730,555
				Filing Date	December 8, 2003
				First Named Inventor	Darwin et al.
				Group Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	3	of	6	Attorney Docket Number	19603/4292 (CRF D-3099-03)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	16	Facchetti et al., "Expression of Inducible Nitric Oxide Synthase in Human Granulomas and Histiocytic Reactions," <i>Am. J. Pathol.</i> 154(1):145-152 (1999)		
	17	Forbes et al., "Divalent-Metal Transport by NRAMP Proteins at the Interface of Host-Pathogen Interactions," <i>Trends Microbiol.</i> 9(8):397-403 (2001)		
	18	Graham et al., "Identification of <i>Mycobacterium tuberculosis</i> RNAs Synthesized in Response to Phagocytosis by Human Macrophages by Selective Capture of Transcribed Sequences (SCOTS)," <i>Proc. Natl. Acad. Sci. USA</i> 96:11554-11559 (1999)		
	19	Grune et al., "Peroxynitrite Increases the Degradation of Aconitase and Other Cellular Proteins by Proteasome," <i>J. Biol. Chem.</i> 273(18):10857-10862 (1998)		
	20	Hernandez-Pando et al., "Persistence of DNA from <i>Mycobacterium tuberculosis</i> in Superficially Normal Lung Tissue During Latent Infection," <i>Lancet</i> 356:2133-2138 (2000)		
	21	Karimova et al., "A Bacterial Two-Hybrid System Based on a Reconstituted Signal Transduction Pathway," <i>Proc. Natl. Acad. Sci. USA</i> 95:5752-5756 (1998)		
	22	Kaushal et al., "Reduced Immunopathology and Mortality Despite Tissue Persistence in a <i>Mycobacterium tuberculosis</i> Mutant Lacking Alternative σ Factor, SigH," <i>Proc. Natl. Acad. Sci. USA</i> 99(12):8330-8335 (2002)		
	23	Keane et al., "Tuberculosis Associated with Infliximab, a Tumor Necrosis-Factor α -Neutralizing Agent," <i>N. Engl. M. Med.</i> 345(15):1098-1104 (2001)		
	24	Kisselev et al., "Proteasome Inhibitors: from Research Tools to Drug Candidates," <i>Chem. Biol.</i> 8(8):739-758 (2001)		
	25	Knipfer et al., "Inactivation of the 20S Proteasome in <i>Mycobacterium smegmatis</i> ," <i>Mol. Microbiol.</i> 25(2):375-383 (1997)		
	26	Langer, T. "AAA Proteases: Cellular Machines for Degrading Membrane Proteins," <i>Trends in Biol. Sci.</i> 25:247-251 (2000)		
	27	Lienhardt et al., "Estimation of the Impact of the Human Immunodeficiency Virus Infection on Tuberculosis: Tuberculosis Risks Re-visited?" <i>Int. J. Tuberc. Lung Dis.</i> 1(3):196-203 (1997)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/730,555
				Filing Date	December 8, 2003
				First Named Inventor	Darwin et al.
				Group Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	4	of	6	Attorney Docket Number	19603/4292 (CRF D-3099-03)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	28	Long et al., "Mycobacteriocidal Action of Exogenous Nitric Oxide," <i>Antimicrob. Agents Chemother.</i> 43(2):403-405 (1999)	
	29	MacMicking et al., "Altered Responses to Bacterial Infection and Endotoxic Shock in Mice Lacking Inducible Nitric Oxide Synthase," <i>Cell</i> 81:641-650 (1995)	
	30	MacMicking et al., "Nitric Oxide and Macrophage Function," <i>Annu. Rev. Immunol.</i> 15:323-350 (1997)	
	31	MacMicking et al., "Identification of Nitric Oxide Synthase as a Protective Locus Against Tuberculosis," <i>Proc. Natl. Acad. Sci. USA</i> 94:5243-5248 (1997)	
	32	Manganelli et al., "Role of the Extracytoplasmic-Function Sigma Factor Sigma(H) in <i>Mycobacterium tuberculosis</i> Global Gene Expression," <i>Mol. Microbiol.</i> 45(2):365-374 (2002)	
	33	Maragos et al., "Mutagenicity of Glyceryl Trinitrate (nitroglycerin) in <i>Salmonella typhimurium</i> ," <i>Mutat. Res.</i> 298(3):187-195 (1993)	
	34	Mogues et al., "The Relative Importance of T Cell Subsets in Immunity and Immunopathology of Airborne <i>Mycobacterium tuberculosis</i> Infection in Mice," <i>J. Exp. Med.</i> 193(3):271-280 (2001)	
	35	Nagy et al., "The 20S Proteasome of <i>Streptomyces coelicolor</i> ," <i>J. Bacteriol.</i> 180(20):5448-5453 (1998)	
	36	Nakata et al., " <i>Mycobacterium Tuberculosis</i> Enhances Human Immunodeficiency Virus-1 Replication in the Lung," <i>Am. J. Resp. & Crit. Care Med.</i> 155:996-1003 (1997)	
	37	Nathan et al., "Reactive Oxygen and Nitrogen Intermediates in the Relationship Between Mammalian Hosts and Microbial Pathogens," <i>Proc. Natl. Acad. Sci. USA</i> 97(16):8841-8848 (2000)	
	38	Nathan et al., "Inducible Nitric Oxide Synthase in the Tuberculous Human Lung," <i>Am. J. Respir. Crit. Care Med.</i> 166:130-131 (2002)	
	39	Nathan et al., in <i>In Tuberculosis, Second Edition</i> , Rom et al., eds., Lippincott Williams & Wilkins, New York, New York, pp. 215-235 (2003)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/730,555
				Filing Date	December 8, 2003
				First Named Inventor	Darwin et al.
				Group Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	5	of	6	Attorney Docket Number	19603/4292 (CRF D-3099-03)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	40	Ogura et al., "AAA Superfamily ATPases; Common Structure- Diverse Function," <i>Genes to Cells</i> 6:575-97 (2001)	
	41	Raman et al., "The Alternative Sigma Factor SigH Regulates Major Components of Oxidative and Heat Stress Responses in <i>Mycobacterium tuberculosis</i> ," <i>J. Bacteriol.</i> 183(20):6119-6125 (2001)	
	42	Raupach et al., "Immune Responses to Intracellular Bacteria," <i>Curr. Opin. Immun.</i> 13:417-428 (2001)	
	43	Rosenkrands et al., "Towards the Proteome of <i>Mycobacterium tuberculosis</i> ," <i>Electrophoresis</i> 21:3740-3756 (2000)	
	44	Russell, " <i>Mycobacterium tuberculosis</i> : Here Today, and Here Tomorrow," <i>Nat. Rev. Mol. Cell. Biol.</i> 2:569-577 (2001)	
	45	Sasseti et al., "Comprehensive Identification of Conditionally Essential Genes in <i>Mycobacteria</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 98(22):12712-12717 (2001)	
	46	Sasseti et al., "Genes Required for <i>Mycobacterial</i> Growth Defined by High Density Mutagenesis," <i>Mol. Microbiol.</i> 48(1):77-84 (2003)	
	47	Scanga et al., "The Inducible Nitric Oxide Synthase Locus Confers Protection Against Aerogenic Challenge of Both Clinical and Laboratory Strains of <i>Mycobacterium tuberculosis</i> in Mice," <i>Infect. Immun.</i> 69(12):7711-7717 (2001)	
	48	Schaible et al., "Cytokine Activation Leads to Acidification and Increases Maturation of <i>Mycobacterium avium</i> -Containing Phagosomes in Murine Macrophages," <i>J. Immunol.</i> 160(3):1290-1296 (1998)	
	49	St. John et al., "Peptide Methionine Sulfoxide Reductase from <i>Escherichia coli</i> and <i>Mycobacterium tuberculosis</i> Protects Bacteria Against Oxidative Damage from Reactive Nitrogen Intermediates," <i>Proc. Natl. Acad. Sci. USA</i> 98(17):9901-9906 (2001)	
	50	Stuehr et al., "Nitric Oxide. A Macrophage Product Responsible for Cytostasis and Respiratory Inhibition in Tumor Target Cells," <i>J. Exp. Med.</i> 169:1543-1555 (1989)	
	51	Tamir et al., "DNA Damage by Nitric Oxide," <i>Chem. Res. Toxicol.</i> 9(5):821-7 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/730,555
				Filing Date	December 8, 2003
				First Named Inventor	Darwin et al.
				Group Art Unit	1646
				Examiner Name	To Be Assigned
Sheet	6	of	6	Attorney Docket Number	19603/4292 (CRF D-3099-03)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	52	Theis et al., "The Nucleotide Excision Repair Protein UvrB, a Helicase-Like Enzyme with a Catch," <i>Mutat. Res.</i> 460:277-300 (2000)	
	53	Vale, RD. "AAA proteins: Lords of the Ring," <i>J. Cell Biol</i> 150(1):F13-19 (2000)	
	54	Walter S., "Structure and Function of the GroE Chaperone," <i>Cell. Mol. Life Sci.</i> 59:1589-1597 (2002)	
	55	Wolf et al., "Characterization of ARC, a Divergent Member of the AAA ATPase Family from <i>Rhodococcus erythropolis</i> ," <i>J. Mol. Biol.</i> 277(1):13-25 (1998)	
	56	Weber et al., "Anaerobic nitrate Reductase (narGHJ) Activity of <i>Mycobacterium bovis</i> BCG <i>in vitro</i> and its Contribution to Virulence in Immunodeficient Mice," <i>Mol. Micro.</i> 35(5):1017-1025 (2000)	
	57	Whalen et al., "Accelerated Course of Human Immunodeficiency Virus Infection after Tuberculosis," <i>Am. J. Resp. & Crit. Care Med.</i> 151:129-135 (1995)	
	58	World Health Organization, "Tuberculosis and AIDS: Statement on AIDS and Tuberculosis," <i>Bulletin Int. Tuber. Lung Dis</i> 64(1):8-11 (1989)	
	59	Zhuang et al., "Nitric Oxide-Induced Mutations in the HPRT Gene of Human Lymphoblastoid TK6 Cells and in <i>Salmonella typhimurium</i> ," <i>Environ. Mol. Mutagen.</i> 35(1):39-47 (2000)	
	60	Zhuang et al., "Mutagenesis Associated with Nitric Oxide Production in Macrophages," <i>Proc. Natl. Acad. Sci. USA</i> 95:8286-8291 (1998)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.